Sign up for our Oncology Central weekly news round-up

First CAR T-cell therapy to eradicate CD19-targeted therapy-resistant leukemia in animal models

Written by Louis Gautier, Future Science Group

A new CAR T-cell therapy has been developed to treat relapsed leukemia, which has developed immunity to CD19-targeted immunotherapy. The therapy has been tested in animal models and will move to human clinical trials next year. It could potentially be used as a first-line treatment. A research group from the City of Hope Institute (CA, USA) has recently published findings in Science Translational Medicine describing the use of a new CAR T-cell therapy for the eradication of CD19-targeted therapy-resistant human leukemia and lymphoma cells. The new therapy targets the B–cell activating factor receptor on cancerous cells and could be used in relapsed patients and, potentially, as a first-line treatment.  The CAR T-cell therapy is currently in its...

To view this content, please register now for access

It's completely free